deltatrials
Completed PHASE2 INTERVENTIONAL NCT00122486

Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

Phase 2 Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV

Sponsor: FHI 360

Conditions HIV Infections
Interventions Tenofovir Disoproxil Fumarate
Updated 5 times since 2017 Last updated: Jul 28, 2006 Started: Jul 31, 2004 Completion: Mar 31, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00122486, this PHASE2 trial focuses on HIV Infections and remains completed. Sponsored by FHI 360, it has been updated 5 times since 2004, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • FHI 360
Data source: FHI 360

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations